Outflow Graft Narrowing of the HeartMate 3 Left Ventricular Assist Device.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
05 2023
Historique:
received: 22 06 2021
revised: 17 10 2021
accepted: 02 12 2021
medline: 25 4 2023
pubmed: 10 1 2022
entrez: 9 1 2022
Statut: ppublish

Résumé

In patients with the HeartMate 3 (HM3, Abbott) left ventricular (LV) assist device (LVAD), outflow graft narrowing has been reported as a result of accumulation of biodebris either internal or external to the graft. This study describes the prevalence, imaging findings, and clinical outcomes associated with HM3 LVAD outflow graft narrowing. A single-center retrospective cohort study was performed in patients who received an HM3 LVAD between November 2014 and July 2019. All patients with a computed tomographic (CT) angiogram or a CT scan with intravenous contrast sufficient to evaluate the outflow graft lumen were included. Narrowing was defined as a hypodensity of ≥3 mm. Of 165 HM3 LVAD recipients, 46 (28%) had qualifying imaging. Outflow graft narrowing was present in 33% (15/46). One patient had complete obstruction requiring emergency surgery, whereas 14 patients had a median hypodensity of 4.5 mm (interquartile range, 3.3-5.8 mm). The presence of outflow graft narrowing was significantly associated with a longer duration of LVAD support (588.2 ± 277.5 days vs 131.5 ± 170.9 days; P < .0001). One-year survival after identification of narrowing was 93%, with death occurring in 1 patient with complete obstruction. LV unloading (mean percent decrease in LV end-diastolic diameter at time of CT imaging vs pre-LVAD) was 16.7% vs 17.7% in patients with and without narrowing, respectively (P = .86). Among patients with adequate imaging, one-third have evidence of narrowing. Outflow graft narrowing secondary to biodebris was more likely to be found in HM3 LVAD recipients with longer duration of LVAD support. There was no significant difference in LV unloading between patients with and without narrowing.

Sections du résumé

BACKGROUND
In patients with the HeartMate 3 (HM3, Abbott) left ventricular (LV) assist device (LVAD), outflow graft narrowing has been reported as a result of accumulation of biodebris either internal or external to the graft. This study describes the prevalence, imaging findings, and clinical outcomes associated with HM3 LVAD outflow graft narrowing.
METHODS
A single-center retrospective cohort study was performed in patients who received an HM3 LVAD between November 2014 and July 2019. All patients with a computed tomographic (CT) angiogram or a CT scan with intravenous contrast sufficient to evaluate the outflow graft lumen were included. Narrowing was defined as a hypodensity of ≥3 mm.
RESULTS
Of 165 HM3 LVAD recipients, 46 (28%) had qualifying imaging. Outflow graft narrowing was present in 33% (15/46). One patient had complete obstruction requiring emergency surgery, whereas 14 patients had a median hypodensity of 4.5 mm (interquartile range, 3.3-5.8 mm). The presence of outflow graft narrowing was significantly associated with a longer duration of LVAD support (588.2 ± 277.5 days vs 131.5 ± 170.9 days; P < .0001). One-year survival after identification of narrowing was 93%, with death occurring in 1 patient with complete obstruction. LV unloading (mean percent decrease in LV end-diastolic diameter at time of CT imaging vs pre-LVAD) was 16.7% vs 17.7% in patients with and without narrowing, respectively (P = .86).
CONCLUSIONS
Among patients with adequate imaging, one-third have evidence of narrowing. Outflow graft narrowing secondary to biodebris was more likely to be found in HM3 LVAD recipients with longer duration of LVAD support. There was no significant difference in LV unloading between patients with and without narrowing.

Identifiants

pubmed: 34998738
pii: S0003-4975(22)00010-8
doi: 10.1016/j.athoracsur.2021.12.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1282-1288

Informations de copyright

Copyright © 2023 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Sneha S Jain (SS)

Division of Cardiovascular Medicine, Stanford University, Palo Alto, California.

Kevin J Clerkin (KJ)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

D Edmund Anstey (DE)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Qi Liu (Q)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Justin A Fried (JA)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Jayant Raikhelkar (J)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Jan M Griffin (JM)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Dylan Marshall (D)

Division of Cardiology, New York-Presbyterian, Weill Cornell, New York, New York.

Paolo Colombo (P)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Melana Yuzefpolskaya (M)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Veli Topkara (V)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Yoshifumi Naka (Y)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Koji Takeda (K)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Gabriel Sayer (G)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Nir Uriel (N)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York. Electronic address: nu2126@cumc.columbia.edu.

Jay Leb (J)

Division of Cardiology, New York-Presbyterian, Columbia University Medical Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH